Glenmede Trust CO Na Blueprint Medicines Corp Transaction History

Glenmede Trust CO Na

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $12,891 - $17,427	-140 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $88,146 - $122,392	-1,544 Reduced 91.69%	140 $10,000
Q4 2019 Feb 12, 2020	BUY	$66.73 - $82.59 $5,271 - $6,524	79 Added 4.92%	1,684 $134,000
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $115,911 - $161,241	1,590 Added 10600.0%	1,605 $117,000
Q2 2019 Aug 13, 2019	BUY	$73.54 - $97.8 $1,103 - $1,467	15 New	15 $1,000

350

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.3B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

Stay updated on Glenmede Trust CO Na with notifications on news.